Selected Open Clinical Trials

For inquiries, visit foxchase.org/ClinicalTrialsProgram or call 888-369-2427.

Breast Cancer

REP0210: A Single Arm, Preoperative, Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients Who Are Candidates for Surgery
Lori J. Goldstein, MD
PDOMPE002/12-055

Gastrointestinal Cancer (Colorectal)

A Phase Ib Study of Twice-Weekly IMMU-130 (hMN-14-SN38 Antibody—Drug Conjugate) in Patients with Colorectal Cancer
Efrat Dotan, MD
PIMMUNO004/12-044

Gastrointestinal Cancer (Pancreas)

An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90 Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
Steven J. Cohen, MD
IMMU-107-04/14-010

Genitourinary Cancer (Renal)

AGS-003-007: An International Phase III Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
David Y.T. Chen, MD, FACS
PARGOS001/12-058

A Phase III, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma
Elizabeth R. Plimack, MD
CA209214/14-043

A Phase Ib, Open Label, Dose-Finding Study of Axitinib in Combination with MK-3475 in Patients with Advanced Kidney Cancer
Elizabeth R. Plimack, MD
14-035

Gynecologic Cancer (Ovarian)

GYN-064: A Phase I/II Trial of Weekly Paclitaxel in Combination with Ganetespib in Patients with Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IND 120407) (NCT01962948)
Lainie P. Martin, MD
ERPGYN064/13-028

CO-338-017: A Phase II, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Ariel 2)
Lainie P. Martin, MD
PCLOV001/13047

Head and Neck Cancer

ECOG 3311: A Phase II Randomized Trial of Transoral Surgical Resection followed by Low-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Miriam N. Lango, MD
ECOG3311/13-203

FER-HN-027: A Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, with Correlative Studies in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT01316757)
Ranee Mehra, MD
FERHN027/10-026

Hematologic Cancer (Lymphoma)

Belinostat plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (BelCHOP) Regimen for Treatment of Patients with Peripheral T cell Lymphoma
Stefan K. Barta, MD, MS, MRCP
SPI-BEL-12-104/14-026

C25003: A Randomized, Open-Label, Phase III Trial of Adcetris® (Brentuximab Vedotin) + AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma
Nadia Khan, MD
C25003/14-022

Sarcoma

A Prospective Correlative Trial of Personalized Patient-Derived Xenograft (PDX or TumorGraft) Modeling in Patients with Metastatic or Recurrent Sarcoma
Sujana Movva, MD
CO-001/108-14

Thoracic Cancer (Non-Small Cell Lung)

CA209026: An Open-Label, Randomized, Phase III Trial of Nivolumab versus Investigator’s Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
Hossein Borghaei, DO
CA209026/14-012

MK-3475-021: A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
Hossein Borghaei, DO
MK-3475-021/14-008

BRF113928: A Phase II study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination with the MEK Inhibitor Trametinib in Subjects with BRAF V600E Mutation Positive Metastatic (Stage IV) Non-Small Cell Lung Cancer
Hossein Borghaei, DO
PGLAXO026

M12-375: A Multicenter, Phase I/Ib, Open-Label, Dose-Escalation Study of ABT-700, a Monoclonal Antibody, in Subjects with Advanced Solid Tumors
Hossein Borghaei, DO
M12-375/14-021